Effects of Adjunct Low-Dose Vitamin D on Relapsing-Remitting Multiple Sclerosis Progression: Preliminary Findings of a Randomized Placebo-Controlled Trial

Table 2

Comparison of Expanded Disability Status Scale (EDSS) and relapses in 50 patients with relapsing-remitting multiple sclerosis before and 12 months after treatment with low-dose vitamin D and placebo.

Treatment group	Number	Baseline Mean (SD)	12 months after therapy Mean (SD)	Differences (95% CI)
	EDSS
Vitamin D	25	1.63 (0.73)	1.63 (0.70)	0.0 (−0.15, 0.15)
Placebo	25	1.70 (1.21)	1.94 (1.41)	−0.24 (−0.40, −0.08)*
	Relapses
Vitamin D	25	1.04 (0.20)	0.32 (0.48)	0.72 (0.50, 0.94)**
Placebo	25	1.04 (0.20)	0.40 (0.58)	0.64 (0.38, 0.90)**

^∗𝑃<0.01, ^∗∗𝑃<0.001, CI: confidence interval.